Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Launched by MAYO CLINIC · Oct 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well a type of treatment called anti-PD-1 therapy works for patients with certain advanced cancers, including melanoma and lung cancer. Researchers want to understand how T cells, which are important parts of our immune system, respond to this treatment. By measuring specific markers in the blood, they hope to find out why some patients respond well to the therapy while others do not. This information could help improve future treatments and monitoring of these cancers.

To participate in the trial, you need to be at least 18 years old and have a confirmed diagnosis of advanced cancer that is appropriate for anti-PD-1 therapy. You should also be able to understand the trial’s requirements and be willing to provide blood samples at specific times throughout the study. Participants will receive the anti-PD-1 treatment and have their responses monitored, which could help doctors learn more about the effectiveness of this therapy. If you're interested, be sure to discuss it with your doctor to see if you meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Are 18 years of age or older
• • Have histologic evidence of locally or regionally advanced or stage IV malignancy
• • Are considered appropriate for starting therapy with anti-PD-1/anti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)
• • Have an understanding of the protocol and its requirements, risks, and discomforts
• • Are willing to undergo peripheral blood collection at the time points mentioned in the protocol
• • Are able and willing to sign an informed consent
• Exclusion Criteria:
• • Inability on the part of the patient to understand the informed consent or be compliant with the protocol
• • Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1/anti-PD-L1 agent as mentioned above)
• • Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception